Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19389455 | 0.92 | GLA (0.48) | GLAPKMSMN1; SMN2CYP1A2MAPK1 | |
| Propane SCHEMBL1995071 | 0.91 | GLA (0.59) | GLAPKMSMN1; SMN2CYP1A2MAPK1 | |
| Alcohol SCHEMBL5801058 | 0.88 | GLA (0.57) | GLAPKMSMN1; SMN2CYP1A2MAPK1 | |
| Alcohol SCHEMBL28379053 | 0.88 | GLA (0.57) | GLAPKMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL7027263 | 0.88 | GLA (0.67) | GLASMN1; SMN2CYP1A2MAPK1L3MBTL1 | |
| SCHEMBL6536452 | 0.88 | GLA (0.67) | GLASMN1; SMN2CYP1A2MAPK1L3MBTL1 | |
| SCHEMBL1069692 | 0.88 | — | — | |
| SCHEMBL3973280 | 0.88 | GLA (0.67) | GLASMN1; SMN2CYP1A2MAPK1L3MBTL1 | |
| SCHEMBL21320454 | 0.87 | CYP1A2 (0.46) | GLAPKMSMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL14182161 | 0.86 | GLA (0.55) | GLAPKMSMN1; SMN2CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| EP-0494956-A4 | AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS | — | 1993-07-21 | — | — | EP | claimed |
| EP-0494956-A1 | AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS. | COSAN CHEM CORP (US) | 1992-07-22 | — | — | EP | claimed |
| WO-1991004952-A1 | AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS | COSAN CHEMICAL CORPORATION (US) | 1991-04-18 | — | — | WO | claimed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230183169-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | Sichuan Academy Of Medical Sciences · Sichuan Provincial People's Hospital (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183169-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | Sichuan Academy Of Medical Sciences · Sichuan Provincial People's Hospital (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183169-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | NOTUM, BYSL, TYR | GLA 4615/4885PKM 3691/4885SMN1; SMN2 2140/4885 |
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | GLA 3997/4885PKM 2513/4885SMN1; SMN2 4092/4885 |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | GLA 1168/4885PKM 1654/4885SMN1; SMN2 1308/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | GLA 3525/4885PKM 2884/4885SMN1; SMN2 3958/4885 |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | GLA 3060/4885PKM 2178/4885SMN1; SMN2 3781/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | GLA 3525/4885PKM 2884/4885SMN1; SMN2 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.